详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Alzheimer's disease - standard of diagnosis, treatment, care, and prevention.

73| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Psychosomatic Medicine, University Medical Center Rostock, Rostock Germany [2]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Rostock/Greifswald, Rostock, Germany [3]Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA [4]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands [5]Lund University, Clinical Memory Research Unit, Lund, Sweden [6]Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy [7]San Raffaele Cassino, Cassino, FR, Italy. [8]Department of Neurogenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Germany [9]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany [10]Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany [11]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China

出处：

DOI：

ISSN：

摘要：

Alzheimer's disease (AD) is the most frequent cause of dementia in people > 60 years. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacological interventions and a healthy lifestyle (diet, socio-affective inclusion, cognitive stimulation, physical exercise, etc.) provide some beneficial effects. Prevention mainly targets modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of those modifiable risk factors.Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区核医学

最新[2023]版：

大类 | 1 区

医学

小类 | 2 区核医学

JCR分区：

出版当年[2020]版：

Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

最新[2023]版：

Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子： 9.1 最新[2023版] 9.1 最新五年平均 10.057 出版当年[2020版] 8.573 出版当年五年平均 7.887 出版前一年[2019版] 11.082 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Psychosomatic Medicine, University Medical Center Rostock, Rostock Germany [2]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Rostock/Greifswald, Rostock, Germany [*1]Department of Psychosomatic Medicine

通讯作者：

通讯机构： [1]Department of Psychosomatic Medicine, University Medical Center Rostock, Rostock Germany [2]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Rostock/Greifswald, Rostock, Germany [*1]Department of Psychosomatic Medicine

推荐引用方式(GB/T 7714)：

APA：

MLA：